Treatment of congenital hyperinsulinism with lanreotide acetate (Somatuline Autogel)

Journal of Clinical Endocrinology and Metabolism

Volumn 96, Issue 8, 2011, Pages 2312-2317

  Modan Moses, Dalit ^a   Koren, Ilana ^b   Mazor Aronovitch, Kineret ^a   Pinhas Hamiel, Orit ^a   Landau, Heddy ^a  

^a Edmond and Lily Safra Children's Hospital   (Israel)

^b CARMEL MEDICAL CENTER   (Israel)

Author keywords

[No Author keywords available]

Indexed keywords

ANGIOPEPTIN; DIAZOXIDE; GLUCOSE; HYDROCHLOROTHIAZIDE; OCTREOTIDE; SOMATULINE AUTOGEL; UNCLASSIFIED DRUG; URSODEOXYCHOLIC ACID;

ARTIFICIAL MILK; BLOOD GLUCOSE MONITORING; CASE REPORT; CHOLELITHIASIS; CONFERENCE PAPER; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; FEMALE; GLUCOSE BLOOD LEVEL; GROWTH; GROWTH RATE; HUMAN; HYPOGLYCEMIA; INFANT; INSULIN PUMP; MALE; NERVOUS SYSTEM DEVELOPMENT; NEWBORN; PERSISTENT HYPERINSULINEMIC HYPOGLYCEMIA OF INFANCY; PRIORITY JOURNAL; SATISFACTION; SIDE EFFECT; TREATMENT DURATION; WEIGHT GAIN;

ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC AGENTS, HORMONAL; FEMALE; HUMANS; INFANT; INFANT, NEWBORN; INJECTIONS, SUBCUTANEOUS; MALE; NESIDIOBLASTOSIS; OCTREOTIDE; PEPTIDES, CYCLIC; SOMATOSTATIN; TREATMENT OUTCOME;

EID: 79961228785     PISSN: 0021972X     EISSN: 19457197     Source Type: Journal    
DOI: 10.1210/jc.2011-0605     Document Type: Conference Paper

References (29)

1. Aynsley-Green A, Hussain K, Hall J, Saudubray JM, Nihoul- FékétéC, De Lonlay-Debeney P, Brunelle F, Otonkoski T, Thornton P, Lindley KJ 2000 Practical management of hyperinsulinism in infancy. Arch Dis Child Fetal Neonatal Ed 82:F98-F107
2. Otonkoski T, Ammälä C, Huopio H, Cote GJ, Chapman J, Cosgrove K, Ashfield R, Huang E, Komulainen J, Ashcroft FM, Dunne MJ, Kere J, Thomas PM 1999 A point mutation inactivating the sulfonylurea receptor causes the severe form of persistent hyperinsulinemic hypoglycemia of infancy in Finland. Diabetes 48:408-415 (Pubitemid 29061118)
3. Mathew PM, Young JM, Abu-Osba YK, Mulhern BD, Hammoudi S, Hamdan JA, Sa'di AR 1988 Persistent neonatal hyperinsulinism. Clin Pediatr (Phila) 27:148-151 (Pubitemid 18087640)
4. de Lonlay P, Fournet JC, Rahier J, Gross-Morand MS, Poggi-Travert F, Foussier V, Bonnefont JP, Brusset MC, Brunelle F, Robert JJ, Nihoul-Fékété C, Saudubray JM, Junien C 1997 Somatic deletion of the imprinted 11p15 region in sporadic persistent hyperinsulinemic hypoglycemia of infancy is specific of focal adenomatous hyperplasia and endorses partial pancreatectomy. J Clin Invest 100:802-807 (Pubitemid 27371697)
5. Ryan F, Devaney D, Joyce C, Nestorowicz A, Permutt MA, Glaser B, Barton DE, Thornton PS 1998 Hyperinsulinism: molecular aetiology of focal disease. Arch Dis Child 79:445-447 (Pubitemid 28496006)
6. Glaser B, Thornton P, Otonkoski T, Junien C 2000 Genetics of neonatal hyperinsulinism. Arch Dis Child Fetal Neonatal Ed 82:F79-F86 (Pubitemid 30305746)
7. González-Barroso MM, Giurgea I, Bouillaud F, Anedda A, Bellanné-Chantelot C, Hubert L, de Keyzer Y, de Lonlay P, Ricquier D 2008 Mutations in UCP2 in congenital hyperinsulinism reveal a role for regulation of insulin secretion. PLoS One 3:e3850
8. Menni F, de Lonlay P, Sevin C, Touati G, Peigné C, Barbier V, Nihoul-Fékété C, Saudubray JM, Robert JJ 2001 Neurologic outcomes of 90 neonates and infants with persistent hyperinsulinemic hypoglycemia. Pediatrics 107:476-479 (Pubitemid 32183179)
9. Meissner T, Wendel U, Burgard P, Schaetzle S, Mayatepek E 2003 Long-term follow-up of 114 patients with congenital hyperinsulinism. Eur J Endocrinol 149:43-51 (Pubitemid 36874203)
10. de Lonlay-Debeney P, Poggi-Travert F, Fournet JC, Sempoux C, Vici CD, Brunelle F, Touati G, Rahier J, Junien C, Nihoul-Fékété C, Robert JJ, Saudubray JM 1999 Clinical features of 52 neonates with hyperinsulinism. N Engl J Med 340:1169-1175 (Pubitemid 29177876)
11. Pinney SE, MacMullen C, Becker S, Lin YW, Hanna C, Thornton P, Ganguly A, Shyng SL, Stanley CA 2008 Clinical characteristics and biochemical mechanisms of congenital hyperinsulinism associated with dominant KATP channel mutations. J Clin Invest 118:2877-2886
12. Mohnike K, Blankenstein O, Pfuetzner A, Pötzsch S, Schober E, Steiner S, Hardy OT, Grimberg A, van Waarde WM 2008 Long-term non-surgical therapy of severe persistent congenital hyperinsulinism with glucagon. Horm Res 70:59-64 (Pubitemid 351919804)
13. Glaser B, Landau H, Permutt MA 1999 Neonatal hyperinsulinism. Trends Endocrinol Metab 10:55-61 (Pubitemid 29287823)
14. Leibowitz G, Glaser B, Higazi AA, Salameh M, Cerasi E, Landau H 1995 Hyperinsulinemic hypoglycemia of infancy (nesidioblastosis) in clinical remission: high incidence of diabetes mellitus and persistent β-cell dysfunction at long-term follow-up. J Clin Endocrinol Metab 80:386-392
15. Glaser B, Hirsch HJ, Landau H 1993 Persistent hyperinsulinemic hypoglycemia of infancy: long-term octreotide treatment without pancreatectomy. J Pediatr 123:644-650 (Pubitemid 23287543)
16. Glaser B, Landaw H 1990 Long-term treatment with the somatostatin analogue SMS 201-995: alternative to pancreatectomy in persistent hyperinsulinaemic hypoglycaemia of infancy. Digestion 45:27-35 (Pubitemid 20088675)
17. Mazor-Aronovitch K, Gillis D, Lobel D, Hirsch HJ, Pinhas-Hamiel O, Modan-Moses D, Glaser B, Landau H 2007 Long-term neurodevelopmental outcome in conservatively treated congenital hyperinsulinism. Eur J Endocrinol 157:491-497 (Pubitemid 350018453)
18. Ludwig A, Ziegenhorn K, Empting S, Meissner T, Marquard J, Holl R, Mohnike K 2011 Glucose metabolism and neurological outcome in congenital hyperinsulinism. Semin Pediatr Surg 20:45-49
19. Mazor-Aronovitch K, Landau H, Gillis D 2009 Surgical versus nonsurgical treatment of congenital hyperinsulinism. Pediatr Endocrinol Rev 6:424-430
20. Gillis D, Landau H, Zangen DH, Glaser B, Glucose intolerance in patients with persistent hyperinsulinemic hypoglycemia of infancy. Program of the 82nd Annual Meeting of The Endocrine Society, Toronto, 2000 (Abstract 2086)
21. Murray RD, Melmed S 2008Acritical analysis of clinically available somatostatin analog formulations for therapy of acromegaly. J Clin Endocrinol Metab 93:2957-2968
22. Heron I, Thomas F, Dero M, Gancel A, Ruiz JM, Schatz B, Kuhn JM 1993 Pharmacokinetics and efficacy of a long-acting formulation of the new somatostatin analog BIM 23014 in patients with acromegaly. J Clin Endocrinol Metab 76:721-727 (Pubitemid 23086495)
23. Caron P, Beckers A, Cullen DR, Goth MI, Gutt B, Laurberg P, Pico AM, Valimaki M, Zgliczynski W 2002 Efficacy of the new long-acting formulation of lanreotide (lanreotide Autogel) in the management of acromegaly. J Clin Endocrinol Metab 87:99-104 (Pubitemid 34084677)
24. Ben-Shlomo A, Melmed S 2008 Somatostatin agonists for treatment of acromegaly. Mol Cell Endocrinol 286:192-198
25. Bakker B, Oostdijk W 2006 Diagnosis and management of congenital hyperinsulinism: a case report. Eur J Endocrinol 155:S153-S155 (Pubitemid 44902276)
26. Krassas GE 2003 Ophthalmic complications in juvenile Graves' disease: clinic and therapeutic approaches. Pediatr Endocrinol Rev 1(Suppl 2):223-229, discussion 229
27. Colao A, Pivonello R, Di Somma C, Tauchmanovà L, Savastano S, Lombardi G 2007 Growth hormone excess with onset in adolescence: clinical appearance and long-term treatment outcome. Clin Endocrinol (Oxf) 66:714-722 (Pubitemid 46699548)
28. Lustig RH, Hinds PS, Ringwald-Smith K, Christensen RK, Kaste SC, Schreiber RE, Rai SN, Lensing SY, Wu S, Xiong X 2003 Octreotide therapy of pediatric hypothalamic obesity: a double-blind, placebo-controlled trial. J Clin Endocrinol Metab 88:2586-2592 (Pubitemid 36724428)
29. Carel JC, Blumberg J, Bougeard-Julien M, Rochiccioli P, Chaussain JL, Tauber M 2009 Lanreotide in Tall Stature Study Group. Long-acting lanreotide in adolescent girls with constitutional tall stature. Horm Res 71:228-236